With the explosive growth of biological sequences in this century, medicinal science has been undergoing an unprecedented revolution. Driven by the avalanche of biological sequences generated in the postgenomic age, medicinal science is currently undergoing an unprecedented revolution [1, 2] , as indicated by, but not limited to, the following four aspects.
I. Post Biological Sequence Modification
Cancer and many other major diseases are often caused by a variety of subtle protein modifications, typically by various different post-translational modifications (PTMs or PTLM) in proteins [3, 4] . In order to reveal their pathological mechanisms and find new and revolutionary strategies to treat them, many efforts have been made with the aim to predict the possible modified sites in various proteins concerned (see, e.g., [5] [6] [7] [8] [9] [10] [11] [12] and a recent review paper [13] ). Meanwhile, to provide efficient tools for the aforementioned researches, the pseudo amino acid composition (PseAAC ) [14] and general PseAAC [15] were proposed. And the corresponding web-servers have been established [16] [17] [18] [19] that can be used by researchers to generate various different modes of PseAAC to catch the key features of protein/peptide sequences according to their needs. The concept of PseAAC and its approaches to deal with protein/peptide sequences have been widely used in medical science and related areas (see, e.g., [11, as well as the Editorial [47] for a special Molecular Science issue focused on "Drug Development and Biomedicine"). Similar subtle modifications, the post-replication modification (PTRM) and post-transcription modification (PTCM), also occur respectively in DNA [48] and RNA sequences [49] , causing many major diseases as well.
Actually, considerable endeavors to develop highthroughput tools for predicting the possible modified sites of DNA/RNA sequences have also been underway (see, e.g., [1, 13, 50, 51] .
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II. Genome Analysis
Genetic disorders are illnesses caused by one or more abnormalities in the genome, or by changes or variants in genes. To help understand these kinds of genetic or genomic diseases and find revolutionary therapeutic strategies to treat them, many in-depth genome analyses have been carried out recently (see, e.g., [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] and a review paper [70] ). During the process of the aforementioned studies, inspired by the successes of using PseAAC in dealing with protein/peptide sequences, the pseudo K-tuple nucleotide composition or PseKNC was proposed to formulate various feature vectors for DNA/RNA sequences [71] . And the corresponding webservers have been established as well [72] [73] [74] [75] , which can be used by researchers to do the same in computational genomics and genome analysis as done in computational proteomics and proteome analysis.
.
III. Personalized Medicine
Different patients may have different responses to the same drug in clinical treatments even they have the same plasma concentration. The reports from World Health Organization (WHO) indicates that, the percentages of patients having bad responses by using the marketed drugs are 10% ~20%, of which 5% are dead [76] . These kinds of bad responses are mainly due to individual differences, a formidable barrier against clinical treatments and pharmaceutical industry. Therefore, it is an inevitable direction to develop personalized medicines [77] [78] [79] [80] . To realize this, it is important to establish personalized medical profile including personal genome, genetic, or genomic data. Personal genomics is the branch of genomics concerned with the sequencing and analysis of the genome of an individual. Again, the aforementioned tools are very useful in this regard.. . .
IV. Drug-Target Interactions within Cellular Networking
Identifying drug-target interaction is one of the key steps for developing new medicines [81] . A typical tool used for this is molecular docking simulation (see, e.g., [52, [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] ). To conduct molecular docking, however, an indispensable entity is a reliable 3D (three dimensional) structure of the target protein. Although X-ray crystallography is a powerful tool in determining protein 3D structures, not all proteins can be successfully and timely crystallized, particularly for membrane proteins. Although NMR is a very powerful tool for determining the 3D structures of membrane proteins as reported by a series of recent publications (see, e.g., [96] [97] [98] [99] [100] [101] [102] ), it is time-consuming as well. To timely acquire the 3D structural information, one has to resort to various structural bioinformatics tools [90] , including the homologous modelling approach as utilized for a series of protein receptors urgently needed during the drug-developing process [103] [104] [105] [106] [107] [108] [109] [110] and other computational modelling methods [111] [112] [113] . Unfortunately the number of dependable templates for developing high quality 3D protein structures via homology modelling is very limited [90] , while the 3D structure developed purely by the approach of energy minimization or molecular dynamics without a good initial template might be far from the http://sciforum.net/conference/mol2net-1 true structure owing to the local minimization problems. To pre-exclude those compounds, which are not likely to interact with the target proteins concerned, some sequence-based methods (see, e.g., [28, 33, 35, 114, 115] and a review paper [116] ) have been developed that can serve to predict the interaction of the drug compounds with various kinds of target proteins in cellular networking. These newly developed methods can help us enormously in reducing the search scope and speeding up the pace of developing new drugs [117] .
